{{Drugbox
| IUPAC_name = 2-[2-hydroxy-3-[<nowiki>[</nowiki>2-(1''H''-indol-3-yl)-1,1-dimethyl-ethyl]amino]propoxy]benzonitrile
| image = Bucindolol.png

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number = 71119-11-4
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 51045
| ChemSpiderID = 46266
| ChEMBL = 2107546
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = E9UO06K7CE

<!--Chemical data-->
| C=22 | H=25 | N=3 | O=2 
| molecular_weight = 363.45 g/mol
}}

'''Bucindolol''' is a [[binding selectivity|non-selective]] [[beta blocker]] with additional weak [[alpha blocker|alpha-blocking]] properties and some [[Beta blocker#Intrinsic sympathomimetic activity|intrinsic sympathomimetic activity]].<ref name="urlformularyjournal.modernmedicine.com">{{cite web | url = http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Bucindolol-A-beta-blocker-for-the-treatment-of-hea/ArticleStandard/Article/detail/601855 | title = formularyjournal.modernmedicine.com | format = | work = | accessdate = }}</ref><ref name="pmid9467185">{{cite journal |vauthors=Willette RN, Mitchell MP, Ohlstein EH, Lukas MA, Ruffolo RR | title = Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart | journal = Pharmacology | volume = 56 | issue = 1 | pages = 30–6 |date=January 1998 | pmid = 9467185 | doi = 10.1159/000028179| url = http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=pha56030}}</ref> It was under review by the [[Food and Drug Administration|FDA]] in the [[United States]] for the treatment of [[heart failure]] in 2009, but was rejected due to issues pertaining to integrity of data submitted.<ref name="urlformularyjournal.modernmedicine.com"/><ref name="urlFDA rejects bucindolol and questions trial integrity « CardioBrief">{{cite web | url = http://cardiobrief.org/2009/06/02/fda-rejects-bucindolol-and-questions-trial-integrity/ | title = FDA rejects bucindolol and questions trial integrity « CardioBrief | format = | work = | accessdate = }}</ref>

== See also ==
* [[Beta blocker]]
*[[Primidolol]]

== References ==
{{Reflist|2}}

{{Antihypertensives}}
{{Adrenergics}}

[[Category:Beta blockers]]
[[Category:Antihypertensive agents]]
[[Category:Indoles]]
[[Category:Amines]]
[[Category:Alcohols]]
[[Category:Phenol ethers]]
[[Category:Nitriles]]


{{antihypertensive-stub}}